9.1
Bioavailability indicates the fraction of the total administered dose that reaches the systemic circulation as an intact drug.
Different administration routes result in varying bioavailability. For example, the drug directly enters the bloodstream through intravenous injection, providing 100% bioavailability.
However, orally administered drugs pass through the GI tract, get absorbed, and undergo metabolism in the liver, resulting in a lesser dose of the drug reaching the systemic circulation.
An oral drug’s bioavailability depends on enzyme activity in the gut wall or liver, gastric pH, and intestinal motility. It is the ratio of the drug quantity reaching the systemic circulation to the drug quantity administered.
Some drugs, like lidocaine, undergo extensive first-pass metabolism, significantly reducing their bioavailability and ruling out their oral usage.
Bioavailability studies for a new or existing drug indicate their therapeutic utility, absorption efficiency, suitable formulation, and effective administration route.
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in lower bioavailability due to factors such as absorption barriers and metabolic processes.
When a drug is administered orally, it must traverse the gastrointestinal tract, where it undergoes absorption and metabolic processes. The bioavailability of oral drugs depends on several factors, including:
Bioavailability studies are essential in pharmaceutical research and development. These studies evaluate the fraction of the drug reaching systemic circulation and its absorption efficiency. Insights from bioavailability studies help in:
These studies are vital for designing and approving new and improved formulations of existing drugs, ensuring safety, efficacy, and optimal therapeutic outcomes.
Bioavailability indicates the fraction of the total administered dose that reaches the systemic circulation as an intact drug.
Different administration routes result in varying bioavailability. For example, the drug directly enters the bloodstream through intravenous injection, providing 100% bioavailability.
However, orally administered drugs pass through the GI tract, get absorbed, and undergo metabolism in the liver, resulting in a lesser dose of the drug reaching the systemic circulation.
An oral drug’s bioavailability depends on enzyme activity in the gut wall or liver, gastric pH, and intestinal motility. It is the ratio of the drug quantity reaching the systemic circulation to the drug quantity administered.
Some drugs, like lidocaine, undergo extensive first-pass metabolism, significantly reducing their bioavailability and ruling out their oral usage.
Bioavailability studies for a new or existing drug indicate their therapeutic utility, absorption efficiency, suitable formulation, and effective administration route.
From Chapter 9:
Now Playing
Bioavailability and Bioequivalence
949 Views
Bioavailability and Bioequivalence
779 Views
Bioavailability and Bioequivalence
766 Views
Bioavailability and Bioequivalence
453 Views
Bioavailability and Bioequivalence
297 Views
Bioavailability and Bioequivalence
628 Views
Bioavailability and Bioequivalence
1.1K Views
Bioavailability and Bioequivalence
417 Views
Bioavailability and Bioequivalence
572 Views
Bioavailability and Bioequivalence
410 Views
Bioavailability and Bioequivalence
397 Views
Bioavailability and Bioequivalence
458 Views
Bioavailability and Bioequivalence
477 Views
Bioavailability and Bioequivalence
496 Views
Bioavailability and Bioequivalence
497 Views
See More